CA Healthcare Acquisition Corp. (CACH), a SPAC looking to invest in growth-oriented companies in the health care industry, found what it was looking for in London-headquartered LumiraDx Limited. The two entities have reached a definitive merger agreement that will list LumiraDx on Nasdaq under “LMDX” and gives the company a valuation of $5 billion. 

Fried, Frank, Harris, Shriver & Jacobson and Goodwin Procter represented LumiraDx in the transaction, while Sidley Austin represented the SPAC. 

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]